Alivus Life Sciences Q3 FY26 Earnings Call Transcript Released
Alivus Life Sciences reported highest-ever Q3 FY26 revenue of ₹673 crore, up 14.4% QoQ and 4.8% YoY. EBITDA margin reached 36.4%. The company expects high single-digit revenue growth for FY26 and maintained EBITDA margins of 30-32%. CAPEX guidance for FY26 revised to ₹450 crore.
The announcement details record financial results, including revenue and EBITDA margins, along with positive future guidance and strategic updates on capacity expansion and product pipeline. This information is highly material for investors.
The company reported record revenues and margins, with strong growth across segments and positive future guidance, indicating a very favorable financial performance.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced the release of the transcript for its Earnings Call held on January 22, 2026. The call pertained to the third quarter ended December 31, 2025. The company reported its highest ever revenue of ₹673 crores for Q3 FY26, marking a 14.4% growth quarter-on-quarter and 4.8% year-on-year. Gross margin for the quarter stood at 58.9%, and EBITDA margin was 36.4%, both highest ever reported quarterly margins. For the nine months of FY26, revenue reached ₹1,863 crores, with EBITDA margin at 33.3%. The company's non-GPL business showed robust growth of 16.1%. Expansion initiatives at Solapur, Ankleshwar, and Dahej are progressing as planned. The company has 595 DMF and CEP filings globally, with 27 high potent API products in the active grid. Alivus Life Sciences guided for high single-digit revenue growth for FY26 and expects margins to range between 30%-32%. CAPEX for FY26 is now guided at approximately ₹450 crores, deferred from the earlier guidance of ₹600 crores. The company remains net debt-free with strong free cash flow generation.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.